drugset
drugset / Trial / NCT00966966

Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered

NCT00966966 ↗

Phase 1 Completed 17 enrolled Wyeth is now a wholly owned subsidiary of Pfizer Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of multiple doses of Gemfibrozil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of co-administration of SAM-531 and Gemfibrozil.

Timeline

Start
2009-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule 5 mg Oral
Subject Gemfibrozil Small molecule 1200 mg Oral

Indications

No indication recorded.